AHA/ASA guideline recommendations for prevention of stroke in women menopause and postmenopausal hormonal therapy: Difference between revisions
< AHA
(Created page with "__NOTOC__ {{Stroke}} {{CMG}}; {{AE}} {{AO}} ==Overview== ==2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT) == ==References== {{refl...") |
|||
Line 7: | Line 7: | ||
==2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT) == | ==2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT) == | ||
===Postmenopausal Hormonal Therapy=== | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LightCoral"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit) | |||
|- | |||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' HT (CEE with or without medroxyprogesterone) should not be used for primary or secondary prevention of stroke in postmenopausal women. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | |||
|- | |||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''2.''' Selective estrogen receptor modulators, such as raloxifene, tamoxifen, or tibolone, should not be used for primary prevention of stroke. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | |||
|} | |||
==References== | ==References== |
Revision as of 15:46, 11 February 2014
Stroke Main page | |
Diagnosis | |
---|---|
Treatment | |
Case Studies | |
AHA/ASA guideline recommendations for prevention of stroke in women menopause and postmenopausal hormonal therapy On the Web | |
American Roentgen Ray Society Images of AHA/ASA guideline recommendations for prevention of stroke in women menopause and postmenopausal hormonal therapy | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ayokunle Olubaniyi, M.B,B.S [2]
Overview
2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT)
Postmenopausal Hormonal Therapy
Class III (No Benefit) |
"1. HT (CEE with or without medroxyprogesterone) should not be used for primary or secondary prevention of stroke in postmenopausal women. (Level of Evidence: A) " |
"2. Selective estrogen receptor modulators, such as raloxifene, tamoxifen, or tibolone, should not be used for primary prevention of stroke. (Level of Evidence: A) " |